,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,class,nmf_pred
0,1,NCT03611946,Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults,,Completed,No Results Available,Zika Virus,Biological: rZIKV/D4Δ30-713|Biological: Placebo,Frequency of solicited local and general adverse events (AEs)|Frequency of unsolicited AEs|Frequency of medically-attended AEs and serious adverse events (SAEs)|Peak neutralizing antibody titer to ZIKV|Frequency of viremia|Determination of the neutralizing antibody titer to ZIKV,National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 50 Years   (Adult),Phase 1,28.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CIR 318,"July 6, 2018","February 8, 2019","September 1, 2019","August 2, 2018",,"January 18, 2020","Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States|University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03611946/ICF_000.pdf",https://ClinicalTrials.gov/show/NCT03611946,0,0
1,2,NCT02937233,Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study,Z001,Completed,No Results Available,Zika,Biological: Zika Virus Purified Inactivated Vaccine|Other: Placebo,"Incidence, intensity, and relationship to vaccination of solicited local and systemic adverse events|Incidence, intensity, and relationship to vaccination of unsolicited local and systemic adverse events|Incidence, intensity, and relationship to vaccination of serious local and systemic adverse events|ZIKV microneutralization Log10 MN50 titers|Zika Env-specific Log10 endpoint ELISA titers|Zika Plaque reduction neutralization test titer|IFN-γ ELISPOT responses to prM, Env, Cap, and NS1 peptides",Kathryn Stephenson|Walter Reed Army Institute of Research (WRAIR)|National Institute of Allergy and Infectious Diseases (NIAID)|Beth Israel Deaconess Medical Center,All,18 Years to 50 Years   (Adult),Phase 1,36.0,Other|U.S. Fed|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2016P000268,"December 8, 2016","June 4, 2018","June 4, 2018","October 18, 2016",,"August 23, 2018","Center for Virology and Vaccine Research Clinical Trials Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02937233,0,0
2,3,NCT04064905,"Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults",,Recruiting,No Results Available,Zika Virus,Biological: mRNA-1893|Other: Placebo,"Frequency and grade of each solicited local and systemic reactogenicity adverse event (AE)|Frequency and grade of any unsolicited AEs|Frequency of any medically attended adverse event (MAAE), serious adverse event (SAE), and adverse event of special interest (AESI)|Geometric mean titer (GMT) of serum neutralizing antibodies (nAb) against zika virus (ZIKV) as measured by Plaque Reduction Neutralization Test (PRNT)|GMT of nAb in initially seronegative participants against ZIKV as measured by PRNT|GMT of nAb in initially seropositive participants against ZIKV as measured by PRNT|Percentage of participants who seroconverted|Proportion of initially seronegative participants with a seroresponse as measured by PRNT|Proportion of initially seropositive participants with a 2-fold or 4-fold increase in nAb titers as compared with baseline as measured by PRNT","ModernaTX, Inc.|Biomedical Advanced Research and Development Authority",All,18 Years to 49 Years   (Adult),Phase 1,120.0,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",mRNA-1893-P101|BARDA HHS010020160029C,"July 30, 2019",February 2021,July 2021,"August 22, 2019",,"November 13, 2019","Meridan Clinical Research, Omaha, Nebraska, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04064905,0,0
3,4,NCT03158233,Zika Case Definition and Surveillance Study,,Completed,No Results Available,Zika Virus Disease,,Number of participants with suspected ZVD and virologically confirmed Zika (VCZ) infection in the cohort|Summary of the signs and symptoms accompanying suspected ZVD and VCZ cases in the study participants,"Sanofi Pasteur, a Sanofi Company|Sanofi",All,"15 Years to 40 Years   (Child, Adult)",,2400.0,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,VAG00001,"April 29, 2017","December 19, 2018","December 19, 2018","May 18, 2017",,"May 24, 2019","Investigational Site, Floridablanca, Santander, Colombia|Investigational Site, Cali, Valle Del Cauca, Colombia|Investigational site, Tegucigalpa, Honduras|Investigational Site, Acapulco, Guerrero, Mexico|Investigational Site, Temixco, Morelos, Mexico|Investigational Site, Carolina, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03158233,0,0
4,5,NCT04182685,"Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua",,Enrolling by invitation,No Results Available,Zika Virus,,Prevalence of short-term self-reported neurological symptoms among ZIKV-exposed|Prevalence of short-term clinically-observed neurological symptoms among ZIKV-exposed|Incidence of long-term clinically-observed neurological sequelae|Incidence of long-term self-reported neurological sequelae|Neurocognitive function|Nonverbal Intelligence|Behavioral problems|Depression|Anxiety|Sleep problems,"RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of North Carolina, Chapel Hill|Sustainable Sciences Institute (Managua, Nicaragua)|Ministry of Health Nicaragua",All,5 Years to 15 Years   (Child),,450.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,CNDR CIRE-16/07/19-099.Ver2|1R21HD095420-01A1,"October 1, 2019","June 1, 2020","June 1, 2020","December 2, 2019",,"February 5, 2020","Health Center Socrates Flores Vivas, Managua, Nicaragua",,https://ClinicalTrials.gov/show/NCT04182685,0,0
5,6,NCT04033068,Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP,MV-ZIKA-RSP,Recruiting,No Results Available,Zika Virus Infection,Biological: Two MV-ZIKA-RSP vaccinations (high dose)|Biological: Two MV-ZIKA-RSP vaccination (low dose)|Biological: One MV-ZIKA-RSP vaccination (high dose) and one placebo|Other: Two placebo injection,Frequency of Adverse Events|Functional anti-zika antibodies as measured by PRNT50 and ELISA|Induction of Zika specific T-cells assessed by FN-ɣIL-2 ELISPOT and FACS assays|Adverse Events and Serious Adverse Events,Themis Bioscience GmbH,All,18 Years to 55 Years   (Adult),Phase 1,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MV-ZIKA-RSP|2019-000840-93,"August 8, 2019","July 1, 2020","September 3, 2020","July 25, 2019",,"August 13, 2019","Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT04033068,0,0
6,7,NCT03229421,Dermatologic Manifestations of Zika Virus,DMZV,Withdrawn,No Results Available,Zika Virus Symptoms and the Associated Exanthema,Other: Survey,Number of days with specific symptoms|Frequency measures of initial clinical presentations,Northwestern University|Pontificia Universidad Catolica Madre y Maestra,All,"18 Years and older   (Adult, Older Adult)",,0.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,STU00205325,"July 6, 2017","December 31, 2018","December 31, 2018","July 25, 2017",,"February 4, 2019","Pontificia Universidad Catolica Madre y Maestra, Departamento de Medicina, Santo Domingo, Illinois, Dominican Republic",,https://ClinicalTrials.gov/show/NCT03229421,0,0
7,8,NCT02996890,"Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability",,Completed,No Results Available,Zika Virus,Biological: MV-ZIKA|Other: Placebo,Immunogenicity: Functional anti-Zika antibodies as measured by PRNT,Themis Bioscience GmbH,All,18 Years to 55 Years   (Adult),Phase 1,48.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MV-ZIKA-101|2016-004212-34,"April 4, 2017","January 4, 2018","April 17, 2018","December 19, 2016",,"April 26, 2018","Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria|Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02996890,0,0
8,9,NCT03106714,Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil,ZikaBra,"Active, not recruiting",No Results Available,Zika Virus,Diagnostic Test: RT-PCR,Persistence and duration of ZIKV,"Oswaldo Cruz Foundation|World Health Organization|Ministry of Health, Brazil|Walter Reed Army Institute of Research (WRAIR)|Wellcome Trust|National Institutes of Health (NIH)",All,"18 Years and older   (Adult, Older Adult)",,1300.0,Other|U.S. Fed|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ERC.0002786|62518016.6.1001.0008,"July 21, 2017","July 31, 2020","July 31, 2020","April 10, 2017",,"August 13, 2019","Tropical Medicine Foundation, Manaus, Amazonas, Brazil|Research Centre Aggeu Magalhães, Oswaldo Cruz Foundation, Recife, Pernambuco, Brazil|Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT03106714,0,0
9,10,NCT02979938,Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection,,Completed,No Results Available,Zika Virus,Other: Semen analysis and semen PCR for Zika virus,Measurement of the presence (with RT-PCR) of ZIKV in semen|Measurement of the viral load (with ct values) of ZIKV in semen,"Trinidad and Tobago IVF and Fertility Centre|Institute of Tropical Medicine, Belgium",Male,"Child, Adult, Older Adult",,25.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ZIKAFERTI,July 2016,May 2017,August 2017,"December 2, 2016",,"May 7, 2018","Trinidad and Tobago IVF & Fertility Centre, Maraval, Trinidad and Tobago",,https://ClinicalTrials.gov/show/NCT02979938,0,0
10,11,NCT02952833,ZIKA Vaccine in Naive Subjects,,Completed,No Results Available,Zika Virus Infection,Drug: Saline|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV),"Comparison between dosage groups of the duration of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the duration overall and in each dosage group of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison between dosage groups of the frequency of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the frequency of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison between dosage groups of the type of vaccine-related Grade 2 or greater local or systemic reactogenicity|Comparison between dosage groups of the type overall and each dosage group of vaccine-related Grade 3 local, systemic, or laboratory AE|Comparison of study withdrawals, and discontinuation of study vaccination due to any reason between dosage groups.|Duration overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Frequency of new onset chronic medical conditions|Frequency overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Frequency overall and in each dosage group of solicited injection site and systemic reactogenicity.|Frequency overall and in each dosage group of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE.|Severity overall and in each dosage group of solicited injection site and systemic reactogenicity.|Severity overall and in each dosage group of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE.|Type overall and in each dosage group of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccination|Peak GMT overall and by dosage group as measured by ZIKV ELISA and neutralization assay.|Per visit GMT overall and by dosage group as measured by ZIKV ELISA and neutralization assay.|Proportion of subjects overall and by dosage group that seroconvert to ZIKV at each post-vaccination visit by assessing ELISA responses in comparison with baseline|Proportion of subjects overall and by dosage group that seroconvert to ZIKV at each post-vaccination visit by assessing neutralization titers in comparison with baseline",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 49 Years   (Adult),Phase 1,91.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",16-0033|HHSN272200800003C,"October 14, 2016","December 5, 2018","December 5, 2018","November 2, 2016",,"December 7, 2018","Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02952833,0,0
11,12,NCT03624946,Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG),,Completed,No Results Available,Zika Virus Infection|Zika Virus Disease,Biological: Zika Virus Immune Globulin (ZIKV-IG)|Other: Placebo,Assessment of Zika Virus Immune Globulin (ZIKV-IG) safety (Number and severity of adverse events.)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2)|Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz),Emergent BioSolutions,All,18 Years to 55 Years   (Adult),Phase 1,30.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ZK-001,"July 30, 2018","March 6, 2019","March 6, 2019","August 10, 2018",,"July 17, 2019","Syneos Health, Early Phase, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03624946,0,0
12,13,NCT03008122,"Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area",,"Active, not recruiting",No Results Available,Zika Virus Infection,Other: Placebo|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV),"Comparison of study withdrawals and discontinuation of study vaccination due to any reason between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the duration of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the frequency of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Comparison of the type of vaccine-related Grade 3 local, systemic, or laboratory AE, and Grade 2 or greater local or systemic reactogenicity between dosage groups and by pre-vaccination flavivirus immune status|Duration of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of new onset chronic medical conditions reported|Frequency of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of solicited injection site reactogenicity|Frequency of systemic reactogenicity|Frequency of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE|Severity of solicited injection site reactogenicity|Severity of systemic reactogenicity|Severity of unsolicited vaccine-related adverse events (AE), including vaccine-related laboratory AE|Type of serious adverse events (SAE) and adverse events of special interest (AESI) considered related to study vaccine|Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample|Frequency of seroconversion to ZIKV measured by ZIKV ELISA in comparison with baseline sample|Peak GMT as measured by neutralization assay|Peak GMT as measured by ZIKV ELISA|Per Visit GMT as measured by neutralization assay|Per Visit GMT as measured by ZIKV ELISA|Proportion of subjects with at least a 4-fold rise in ZIKV GMT as measured by ZIKV ELISA and neutralization assay compared with baseline overall",National Institute of Allergy and Infectious Diseases (NIAID),All,21 Years to 49 Years   (Adult),Phase 1,91.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",16-0034|HHSN272201300021I,"February 24, 2017","August 2, 2021","August 2, 2021","January 2, 2017",,"February 21, 2020","Ponce School of Medicine CAIMED Center, Ponce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03008122,0,0
13,14,NCT03679728,Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection,,Completed,No Results Available,Zika Virus Infection,Behavioral: First trimester|Behavioral: Second trimester,"Children with microcephaly at birth, whose mothers had zika virus infection in the first or second gestation trimester, showed poor sensorimotor outcomes, mainly impaired muscle tone and antigravity postural control.|Children whose mothers were affected in the first trimester had lower head circumference measures that children whose mothers were affected in the second trimester.",University of Sao Paulo,All,6 Months to 18 Months   (Child),,31.0,Other,Observational,Observational Model: Other|Time Perspective: Cross-Sectional,65822017.3.0000.5390,"August 2, 2016","September 15, 2016","April 16, 2017","September 20, 2018",,"September 20, 2018","School of Arts, Sciences and Humanities of the University of Sao Paulo, Sao Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03679728,0,0
14,15,NCT02963909,"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.",,Completed,No Results Available,Zika Virus Infection,Biological: IXIARO|Other: Placebo|Biological: YF Vax 17D Strain|Biological: Zika Virus Purified Inactivated Vaccine (ZPIV),"Occurrence of SAEs, new onset medical conditions, and AESIs|Occurrence of solicited local AEs|Occurrence of solicited systemic AEs|Occurrence of unsolicited AEs|Relationship of unsolicited AEs to vaccination|Severity of solicited local AEs|Severity of solicited systemic AEs|Severity of unsolicited AEs|Anti- ZIKV NAbs GMTs by group in subjects who consent to two doses of ZPIV|Anti- ZIKV NAbs GMTs overall|Anti- ZIKV NAbs seroconversion rates by group in subjects who consent to two doses of ZPIV|Anti- ZIKV NAbs seroconversion rates overall|Anti-ZIKV Nabs GMTs for group 1 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs GMTs for group 2 and 3 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs seroconvertion rates for group 1 subjects who consent to the third dose of ZPIV|Anti-ZIKV Nabs seroconvertion rates for group 2 and 3 subjects who consent to the third dose of ZPIV",National Institute of Allergy and Infectious Diseases (NIAID),All,18 Years to 49 Years   (Adult),Phase 1,75.0,NIH,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",16-0062,"November 1, 2016","October 30, 2018","October 30, 2018","November 15, 2016",,"November 9, 2018","Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02963909,0,0
15,16,NCT03425149,"Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults",,Completed,No Results Available,Zika Virus|Zika Virus Infection,Biological: VLA1601|Biological: Placebo,Rate of subjects with solicited adverse events including injection site and systemic reactions|Rate of subjects with any adverse events (AEs)|Rate of subjects with serious adverse events (SAEs)|Rate of subjects with any IMP-related AEs|Rate of subjects with any IMP-related SAEs|Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination|GMT for ZIKV-specific neutralizing antibody titer after first vaccination|Rate of subjects with seroconversion after last active vaccination|Rate of subjects with seroconversion after first vaccination|Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline|Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline,Valneva Austria GmbH|Emergent BioSolutions,All,18 Years to 49 Years   (Adult),Phase 1,67.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",VLA1601-101,"February 24, 2018","June 26, 2018","November 16, 2018","February 7, 2018",,"July 5, 2019","New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03425149,0,0
16,17,NCT02840487,"Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults",,Completed,No Results Available,Prevention of Zika Infection|Zika-Specific Immune Response,Biological: VRC-ZKADNA085-00-VP,To evaluate the safety and tolerability of four vaccination regimens with ZIKV DNA vaccine (VRC-ZKADNA085-00-VP) administered IM at 4 mg.|To evaluate the magnitude and frequency of ZIKV-specific antibodyresponse as measured by neutralization assay.,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,18 Years to 35 Years   (Adult),Phase 1,80.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,160148|16-I-0148,"August 2, 2016","March 14, 2019","March 14, 2019","July 21, 2016",,"March 18, 2019","Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States|University of Maryland Ctr. for Vaccine Development, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02840487,0,0
17,18,NCT03014089,"Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects",,Completed,No Results Available,Zika Virus,Biological: mRNA-1325|Other: Placebo,"Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI) and adverse events considered related to study drug|Frequency of seroconversion to ZIKV measured by neutralization assay in comparison with baseline sample","ModernaTX, Inc.|Biomedical Advanced Research and Development Authority",All,18 Years to 49 Years   (Adult),Phase 1,90.0,Industry|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",mRNA-1325-P101|HHSO100201600029C,"December 21, 2016",July 2019,July 2019,"January 9, 2017",,"December 9, 2019","San Diego, California, United States|Melbourne, Florida, United States|Peoria, Illinois, United States",,https://ClinicalTrials.gov/show/NCT03014089,0,0
18,19,NCT02996461,"VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults",,Completed,No Results Available,Prevention of Zika Infection|Zika-Specific Immune Response,Biological: VRC-ZKADNA090-00-VP,To evaluate the safety and tolerability of v ZIKV DNA vaccine administered at 4mg IM by needle and syringe.|To evaluate the safety and tolerability of ZIKV DNA vaccine administered at 4 mg IM by Pharma jet.|To evaluate the magnitude and the frequency of ZIKV-specific antibody response as measured by neutralization assay.,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,18 Years to 50 Years   (Adult),Phase 1,45.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,170024|17-I-0024,"December 12, 2016","September 3, 2019","September 3, 2019","December 19, 2016",,"December 17, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02996461,0,0
19,20,NCT02856984,Zika in Infants and Pregnancy (ZIP),,"Active, not recruiting",No Results Available,Zika Virus Disease (Disorder),,Incidence of congenital malformations for ZIKV infected participants|Incidence of adverse fetal outcomes for ZIKV infected participants|Incidence of congenital malformations for ZIKV symptomatic participants|Incidence of adverse fetal outcomes for ZIKV symptomatic participants,RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Environmental Health Sciences (NIEHS)|Oswaldo Cruz Foundation,Female,"15 Years and older   (Child, Adult, Older Adult)",,6461.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,GN ZIKA,June 2016,"May 31, 2020","May 31, 2020","August 5, 2016",,"January 6, 2020","Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS; Rue Waldemar Falcao, Salvador, Bahia, Brazil|Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE, Recife, PE, Brazil|Instituto Fernandes Figueira - FIOCRUZ, Rio de Janeiro, RJ, Brazil|Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - Monte Alegre, Ribeirão Preto, SP, Brazil|Universidad de Antioquia, Medellín, Colombia|Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP), Guatemala, Guatemala|MINSA Central, Managua, Nicaragua|Universidad Peruana, Lima, Peru|University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico|University of Puerto Rico - Recinto de Río Piedras, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02856984,0,0
20,21,NCT02810210,Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of America,ZIKA-DFA-BB,Unknown status,No Results Available,Zika Virus Infection on Fetus and Child During the Pregnancy,Other: fundus examination|Other: Head ultrasound,Embryofoetopathy incidence within cohort 1 and 3|Comparison of congenital abnormality incidence rates between cohorts 1 and 3,"Institut National de la Santé Et de la Recherche Médicale, France",All,up to 2 Years   (Child),,2220.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-19,June 2016,September 2017,September 2018,"June 22, 2016",,"August 30, 2016","CH de la Basse Terre, Basse-terre Cedex, France|CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, Fort de France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH LC Fleming, Saint Martin Cedex, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,https://ClinicalTrials.gov/show/NCT02810210,0,0
21,22,NCT03263195,Prospective Cohort Study of HIV and Zika in Infants and Pregnancy,HIV ZIP,"Active, not recruiting",No Results Available,HIV|Zika Virus|Pregnant Women,,"Enrollment (150 HIV-infected and 50 HIV-uninfected pregnant women within one year, with a minimum of 20 of these women having HIV/ZIKV co-infection by their end of pregnancy).|Viral suppression (in HIV-infected women with ZIKV co-infection compared to those without ZIKV co-infection during pregnancy and at the time of delivery).|Incidence of ZIKV infection (among pregnant women with HIV infection compared to those without HIV infection).|Incidence of adverse pregnancy outcomes (in women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of vertical transmission of HIV and ZIKV (in women co-infected with HIV and ZIKV and women infected with either HIV or ZIKV alone).|Incidence of congenital malformations (among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of other adverse outcomes among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone.|Growth, as measured by length, weight, and head circumference (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Audiologic function as assessed by hearing levels, acoustic immitance, and otoacoustic emissions (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Ophthalmologic structure and function as assessed by ophthalmoscopy, fixation, and acuity card testing (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Neurodevelopment as assessed by the Bayley III and Ages and Stages Questionnaires- 3rd Edition (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).",Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Female,"15 Years and older   (Child, Adult, Older Adult)",,395.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,HIV-ZIP,"August 23, 2017",August 2020,August 2020,"August 28, 2017",,"February 5, 2020","University of Miami Pediatric/Prenatal HIV/AIDS, Miami, Florida, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Baylor College of Medicine; Texas Children's Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|University of Sao Paulo at Riberaio Preto Brazil, São Paulo, Brazil|University of Puerto Rico Pediatrics HIV/AIDS Research Program, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03263195,0,0
22,23,NCT03393286,ZIKAlliance Children Cohort (ZIKAllianceCH),ZIKAllianceCH,Recruiting,No Results Available,Zika Virus,,"Congenital Abnormalities detected after birth as defined by the evolving definition of the congenital zika syndrome|Hearing abnormalities measured after birth|Visual abnormalities measured after birth|Developmental / cognitive abnormalities measured by the Ages and Stages 3rd Edition (ASQ3)|Developmental / cognitive abnormalities measured by the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)",University of Heidelberg Medical Center,All,up to 6 Months   (Child),,5000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,734548CH (EC   H2020   RIA),"January 15, 2018","September 30, 2019","September 30, 2020","January 8, 2018",,"May 10, 2019","Sosecali Ltd. (SOSE), Guaqui, Bolivia|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, São Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-à-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), Mérida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,https://ClinicalTrials.gov/show/NCT03393286,0,1
23,24,NCT02733796,Persistence of Zika Virus in Semen After Acute Infection,,"Active, not recruiting",No Results Available,Zika Virus|Zika Virus Disease|Virus Shedding|Transmission,,Incidence rate of ZIKV persistence in semen|kinetics of ZIKV persistence in semen|replication fitness of ZIKV in semen|comparison of ZIKV sequences from semen vs. non-semen samples,"Institute of Tropical Medicine, Belgium",Male,"18 Years to 80 Years   (Adult, Older Adult)",,15.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,B300201628191,March 2016,January 2019,January 2019,"April 12, 2016",,"April 12, 2018","ITM, Antwerp, Belgium",,https://ClinicalTrials.gov/show/NCT02733796,0,0
24,25,NCT03330600,Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome,,Completed,No Results Available,Zika Virus Infection|Microcephaly,Behavioral: aquatic physicotherapy|Behavioral: immersion,change in Modified Tardieu Scale|change in heart rate|change in respiratory frequency|change in oxygen saturation|change in body temperature,Universidade Federal de Pernambuco,All,3 Months to 24 Months   (Child),Not Applicable,12.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",Projeto Milena LEPed,"June 1, 2017","February 18, 2018","October 30, 2018","November 6, 2017",,"May 7, 2019","Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,https://ClinicalTrials.gov/show/NCT03330600,0,0
25,26,NCT02916732,Zika Virus Infection's Pregnancy Consequences in French Department of America,ZIKA-DFA-FE,Unknown status,No Results Available,Incidence of ZIKV Infection on Fetus During the Pregnancy,,Incidence of ZIKV infection during pregnancy|Incidence of microcephaly and other fetal abnormalities,"Institut National de la Santé Et de la Recherche Médicale, France",Female,18 Years to 60 Years   (Adult),,26980.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,C16-08|2016-A00399-42,April 2016,January 2018,January 2019,"September 27, 2016",,"September 27, 2016","CH Andrée Rosemon (CHAR), Cayenne Cedex, France|CHU de Martinique, Fort de France Cedex, France|CHU de Pointe à Pitre/Les Abymes, Pointe A Pitre, France|CH de l'Ouest Guyanais Franck Joly (CHOG), Saint-laurent-du-maroni, France",,https://ClinicalTrials.gov/show/NCT02916732,0,0
26,27,NCT03443830,Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans,,Completed,No Results Available,Treatment of Acute Zika Virus Infection,Drug: Tyzivumab,Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Maximum Concentration (Cmax) - Pharmacokinetic Assessment|Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment|Area Under the Curve Extrapolated to Infinity (AUC0-∞) - Pharmacokinetic Assessment|AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment|Half-Life (t1/2) - Pharmacokinetic Assessment|Volume of Distribution (Vd) - Pharmacokinetic Assessment|Clearance [CL] - Pharmacokinetic Assessment|Anti-Drug Antibody Assessment,"Tychan Pte Ltd.|Duke-NUS Graduate Medical School|Singapore Clinical Research Institute|National University, Singapore|National University Hospital, Singapore",All,21 Years to 45 Years   (Adult),Phase 1,24.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZKT-001,"February 8, 2018","September 12, 2018","December 4, 2018","February 23, 2018",,"April 10, 2019","SingHealth Investigational Medicine Unit, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03443830,0,0
27,28,NCT03255369,Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF),ZIKVIRUSIFF,Unknown status,No Results Available,ZIKA VIRUS INFECTION|Child Development|Microcephaly,Other: Child exposed Zika virus proved,Microcephaly and/or delay in development|ocular injury and cognitive disorder in Bayley Test 3rd edition|Hearing injury and language delay in Bayley Test 3rd edition,Oswaldo Cruz Foundation|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,up to 3 Years   (Child),,500.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,52675616.0.0000.5269,"January 2, 2016","December 30, 2018","December 30, 2019","August 21, 2017",,"May 3, 2018","Instituto Fernandes Figueira/Fiocruz, Rio de Janeiro, RJ, Brazil",,https://ClinicalTrials.gov/show/NCT03255369,0,0
28,29,NCT03776695,Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients,,Recruiting,No Results Available,Treatment of Acute Zika Virus Infection,Biological: Tyzivumab|Other: Placebo,Incidence of Treatment-Emergent Adverse Event (Safety and Tolerability)|Viral Clearance Post-Tyzivumab Infusion (Efficacy),Tychan Pte Ltd.|Singapore Clinical Research Institute|Duke-NUS Graduate Medical School,All,21 Years to 60 Years   (Adult),Phase 1,28.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ZKT-002|CTA1800062,"October 9, 2018","December 31, 2020","December 31, 2020","December 17, 2018",,"December 17, 2018","SingHealth Investigational Medicine Unit, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT03776695,0,0
29,30,NCT04015648,Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001),,Recruiting,No Results Available,Zika|Chikungunya,"Biological: ChAdOx1 Zika|Biological: ChAdOx1 Zika, ChAdOx1 Chik",Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of solicited adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of unsolicited adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of serious adverse events.|Safety and tolerability of ChAdOx1 Zika given as a standalone vaccine or co-administered with ChAdOx1 Chik at different doses in healthy adult volunteers assessed by the occurrence of laboratory adverse events.|Measures of humoral immunogenicity to the ChAdOx1 ZIKA and ChAdOx1 CHIK vaccines|Measures of cellular immunogenicity to the ChAdOx1 ZIKA and ChAdOx1 CHIK vaccines,University of Oxford,All,18 Years to 50 Years   (Adult),Phase 1,57.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZIKA001,"October 21, 2019","July 1, 2021","July 1, 2021","July 11, 2019",,"January 9, 2020","CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT04015648,0,0
30,31,NCT03188731,ZIKAlliance Pregnant Women Cohort,ZIKAlliancePW,"Active, not recruiting",No Results Available,Zika Virus|Pregnancy Related,,Congenital Abnormalities,"University of Heidelberg Medical Center|European Union|ZIKAlliance|Oswaldo Cruz Foundation|University of Sao Paulo|London School of Hygiene and Tropical Medicine|Federal University of Bahia|Universidade Federal de Goias|University Medical Center Groningen|University of Carabobo|Universidad Industrial de Santander|Sosecali Hospital, Guyaquil|Tropical Medicine Institute Pedro Kourí, Cuba|Mexican National Institute of Public Health|Instituto Mexicano del Seguro Social|Institut National de la Santé Et de la Recherche Médicale, France|Erasmus Medical Center",Female,"16 Years to 45 Years   (Child, Adult)",,5000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,734548PW (EC   H2020   RIA),"May 24, 2017","September 30, 2019","September 30, 2020","June 15, 2017",,"September 30, 2019","Sosecali Ltd. (SOSE), Guaqui, Bolivia|INSERM, Santa Cruz, Bolivia|Federal University of Bahia (UFB), Bahia, Brazil|Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Federal University of Goias, Goiás, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Recife, Brazil|Fundacao Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil|University of Sao Paulo, São Paulo, Brazil|Industrial University of Santander (UIS), Bucaramanga, Colombia|Pedro Kouri Institute (IPK), Havana, Cuba|INSERM, Pointe-à-Pitre, Guadeloupe|IMSS Mexico (IMSS), Guadalajara, Mexico|National Institute of Public Health (INSP), Mérida, Mexico|Universidad de Carabobo / UMC Groningen (UMCG), Valencia, Venezuela",,https://ClinicalTrials.gov/show/NCT03188731,0,1
31,32,NCT02831699,"The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico",Zik01,Completed,No Results Available,Zika Virus Disease (Disorder)|Dengue|Chikungunya,,"The proportion of subjects that have confirmed Zika, Chikungunya, or Dengue (including co-infections) from the subjects presenting with fever and/or rash in southeastern Mexico.","Mexican Emerging Infectious Diseases Clinical Research Network|Secretaria de Salud, Mexico|National Institute of Allergy and Infectious Diseases (NIAID)",All,"1 Year and older   (Child, Adult, Older Adult)",,600.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,Zik01,"June 21, 2016","January 25, 2019","January 25, 2019","July 13, 2016",,"December 20, 2019","Hospital General de Tapachula, Tapachula, Chiapas, Mexico|Hospital Regional de Alta Especialidad Ciudad Salud, Chiapas, Mexico|Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Clínica Hospital Dr. Roberto Nettel Flores, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Hospital General de Zona con Medicina Familiar No. 1, Chiapas, Mexico|Instituto Mexicano del Seguro Social (IMSS) Delegación Estatal / Unidad de Medicina Familiar No. 11, Chiapas, Mexico|Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico",,https://ClinicalTrials.gov/show/NCT02831699,0,0
32,33,NCT03161444,Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.,ZIKAVIH,Recruiting,No Results Available,HIV Infections|Zika Virus Infection,Other: Biological sample collection,"Presence or not of Zika virus-specific immunoglobulin G antibodies in the serum taken after the epidemic|Existence or not of clinical signs evocating of an episode of disease with Zika virus.|Presence or not of Dengue virus specific antibodies before the outbreak of Zika virus infection, sought on the samples taken at the end of the chikungunya epidemic.|Presence or not of Chikungunya-specific antibodies before the outbreak of Zika virus infection, sought after sampling at the end of the chikungunya epidemic.|Evolution of the CD4 lymphocyte levels before and after the outbreak of Zika virus|Evolution of the HIV1 RNA levels before and after the outbreak of Zika virus",University Hospital Center of Martinique|University Hospital of Guadeloupe,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,362.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,16/B/06|2016-A01173-48,"March 21, 2017",July 2018,December 2018,"May 19, 2017",,"March 20, 2018","University Hospital of Martinique, Fort-de-France, France|University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe",,https://ClinicalTrials.gov/show/NCT03161444,0,0
33,34,NCT03204409,ZIKAlliance Natural History Study,ZIKAllianceNH,Suspended,No Results Available,Zika Virus|Zika Virus Infection,,ZIKA Virus Infection|DENGUE Virus Infection|Chikungunya Virus Infection,University of Heidelberg Medical Center|University of Sao Paulo,All,"18 Years and older   (Adult, Older Adult)",,1000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,734548NH (EC   H2020   RIA),"April 1, 2018","December 31, 2019","September 3, 2020","July 2, 2017",,"April 18, 2019","University of Sao Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03204409,0,0
34,35,NCT03343626,"Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants",,"Active, not recruiting",No Results Available,"Virus, Zika|Zika Virus Disease|Flavivirus Infections|Healthy Participants",Drug: Placebo|Biological: PIZV,"Percentage of Participants With Solicited Local Injection Site Reactions Within 7 Days After Dose 1 of PIZV or Placebo|Percentage of Participants With Solicited Local Injection Site Reactions Within 7 Days After Dose 2 of PIZV or Placebo|Percentage of Participants With Solicited Systemic Adverse Events (AEs) Within 7 Days After Dose 1 of PIZV or Placebo|Percentage of Participants With Solicited Systemic AEs Within 7 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one Non-serious Unsolicited AE Within 28 Days After Dose 1 of PIZV or Placebo|Percentage of Participants who Experience at Least one Non-serious Unsolicited AE Within 28 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one Serious Adverse Event (SAE) Within 28 Days After Dose 1 of PIZV or Placebo|Percentage of Participants who Experience at Least one Serious Adverse Event (SAE) Within 28 Days After Dose 2 of PIZV or Placebo|Geometric Mean Neutralizing Antibody Titers (GMTs) of Zika Virus (ZIKV) 28 Days After Dose 2 of PIZV or Placebo|Percentage of Participants who Experience at Least one SAE During the Study|Geometric Mean Neutralizing Antibody Titers (GMTs) of ZIKV 28-days After Dose 1, 6, 12 and 24-months After Dose 2 in Applicable Groups|Seropositivity Rate for PIZV 28 Days After Dose 1, 28 Days After Dose 2, 6 Months, 12 Months and 24 Months After Dose 2 in Applicable Groups|Seroconversion Rate for PIZV 28 Days Post Dose 1 and 2",Takeda,All,18 Years to 49 Years   (Adult),Phase 1,271.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention",ZIK-101|U1111-1201-5778,"November 13, 2017","December 28, 2018","November 19, 2020","November 17, 2017",,"March 26, 2019","Clinical Research of South Florida, Coral Gables, Florida, United States|Miami Research Associates, Miami, Florida, United States|AppleMed Research, Miami, Florida, United States|Johnson County Clin-Trials, Lenexa, Kansas, United States|Regional Clinical Research Inc., Endwell, New York, United States|Rochester Clinical Research, Rochester, New York, United States|Tekton Research, Austin, Texas, United States|Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico|Ponce Medical School Foundation, Santurce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03343626,0,0
35,36,NCT03227601,Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome,,Unknown status,No Results Available,Zika Virus,Device: posture adapter,Body Alignment|Motor function|Gastrointestinal function|Muscular tonus,Universidade Federal de Pernambuco,All,12 Months to 24 Months   (Child),Not Applicable,20.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1808,"July 20, 2017","October 19, 2017","August 31, 2018","July 24, 2017",,"July 24, 2017","Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil",,https://ClinicalTrials.gov/show/NCT03227601,0,0
36,37,NCT02794181,Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD),,Completed,No Results Available,Zika Virus|Dengue Virus|Chikungunya Virus Infections,,"Prevalence of ZIKV, DENV and CHIKV infection (RNA-positives) among travel-deferred adult blood donors in the study population.|Prevalence of ZIKV infection (RNApositives) among adult blood donors with a history of potential sexual exposure to ZIKV infection, in the study population.|24-week Natural History of ZIKV, DENV and CHIKV (RNA-positives).",National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",,34.0,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,160124|16-CC-0124,"June 8, 2016","March 14, 2019","March 14, 2019","June 9, 2016",,"March 18, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02794181,0,0
37,38,NCT04118738,International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy,,Recruiting,No Results Available,Zika|Neurodevelopmental Abnormality|Hearing Loss|Growth Delay|Eye Abnormalities,,Neurodevelopmental outcome at age18 months|Neurodevelopmental outcome at age 24 months|Neurodevelopmental outcome at age 30 months|Neurodevelopmental outcome at age 36 months|Neurodevelopmental outcome at age 42 months|Anthropometric Measurements: Height|Anthropometric Measurements: Weight|Anthropometric Measurements: Head circumference|Anthropometric Measurements: Mid upper arm circumference|Hearing assessment by Otoacustic Emissions (OAE) and Visual Reinforcement Audiometry (VRA)|Comprehensive ophthalmologic evaluation.,Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|Oswaldo Cruz Foundation (Fiocruz),All,18 Months to 42 Months   (Child),,400.0,Other|NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,ZIP 2.0,"June 12, 2019",July 2021,July 2021,"October 8, 2019",,"October 8, 2019","Departamento de Medicina Tropical da Universidade Federal de Pernambuco- UFPE, Recife, Pernambuco, Brazil|Instituto Fernandes Figueira - FIOCRUZ, Rio De Janeiro, Brazil|Asociación Civil Selva Amazónica, Iquitos, Loreto, Peru|Puerto Rico Medical Center- Maternal Infant Studies Center (CEMI), San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT04118738,0,0
38,39,NCT03776903,Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA,,Completed,No Results Available,Zika Virus Infection,Other: ZIKV Detect™ 2.0 IgM Capture ELISA,Positive Percent Agreement and Negative Percent Agreement|Duration of Positive Percent Agreement,"InBios International, Inc.|Fast-Track Drugs & Biologics, LLC|Biomedical Advanced Research and Development Authority",All,"Child, Adult, Older Adult",,600.0,Industry|Other|U.S. Fed,Observational,Observational Model: Cohort|Time Perspective: Other,ZIKV-2016-01,"April 1, 2018","August 31, 2018","September 30, 2018","December 17, 2018",,"December 17, 2018","InBios International, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03776903,0,0
39,40,NCT02874456,Pilot Study to Detect Zika Virus in Sperm,ZIKSPERM,Completed,No Results Available,Viruses,Other: virus detection,presence of Zika virus on RNA by polymerase chain reaction,"University Hospital, Toulouse|Centre Hospitalier Universitaire de Pointe-a-Pitre|Institut Pasteur",Male,18 Years to 45 Years   (Adult),Not Applicable,15.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RC31/16/7941,"May 6, 2016",December 2017,December 2017,"August 22, 2016",,"July 19, 2019","University Hospital, Pointe-à-Pitre, Guadeloupe",,https://ClinicalTrials.gov/show/NCT02874456,0,0
40,41,NCT02943304,Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero,ZEN Iniciative,Recruiting,No Results Available,Microcephaly|Mental Retardation,"Other: Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV",Neurodevelopmental Outcome|Fetal CNS Impairment,"Universidad Industrial de Santander|University of North Carolina, Chapel Hill|Michigan State University",Female,"13 Years to 50 Years   (Child, Adult)",,440.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,4110,May 2016,December 2019,December 2020,"October 24, 2016",,"January 17, 2019","Hospital Universitario de Santander, Bucaramanga, Santander, Colombia",,https://ClinicalTrials.gov/show/NCT02943304,0,0
41,42,NCT03110770,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,DNA,Completed,No Results Available,Zika Virus|Zika Virus Infection|Virus Diseases|Flavivirus Infections|Flaviviral Diseases|Flaviviridae Infections|RNA Virus Infections,Biological: VRC-ZKADNA090-00-VP|Other: VRC-PBSPLA043-00-VP,Local Reactogenicity (Part A and B)|Systemic Reactogenicity (Part A and B)|Laboratory measures (Part A)|Laboratory measures (Part B)|Serious adverse events (Part A)|Serious adverse events (Part B)|New chronic medical conditions (Part A)|New chronic medical conditions (Part B)|Confirmed cases of Dengue virus infection (Part A)|Confirmed cases of Dengue virus infection (Part B)|Unsolicited adverse events (Part A and B)|Confirmed cases of Zika with symptoms (Part B only)|Antibody response to VRC-ZKADNA090-00-VP (Part A and B)|Confirmed cases of Zika (Part B only),"National Institute of Allergy and Infectious Diseases (NIAID)|The Emmes Company, LLC|Leidos Biomedical Research, Inc.|FHI Clinical, Inc.|PPD",All,"15 Years to 35 Years   (Child, Adult)",Phase 2,2338.0,NIH|Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",VRC 705,"March 29, 2017","October 4, 2019","October 4, 2019","April 12, 2017",,"December 24, 2019","QPS-Miami Research Associates, Miami, Florida, United States|Doctors Hospital at Renaissance, Edinburg, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Hospital Das Clinicas Da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil|Centro de Pesquisas Clínicas Do Instituto Central Do Hospital Das Clínicas Da FMUSP, São Paulo, SP, Brazil|Clinica de la Costa Ltda, Barranquilla, Atlantico, Colombia|Centro de Atencion y Diagnostico de Enfermedades Infecciosas, Bucaramanga, Santander, Colombia|CCIM Costa Rican Center Center of Medical Research, Sociedad Anonima, San José, Los Yoses, Costa Rica|AGA Clinical Centro de Investigaciones, Guayaquil, Guayas, Ecuador|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Instituto Conmemorativo Gorgas, Panamá, San Miguelito Province, Panama|Asociacion Civil Selva Amazonica, Iquitos, Maynas/Loreto, Peru|Unidad de Ensayos (UNIDEC) del Policlinico Universidad Nacional Mayor de San Marcos, Lima, Peru|Ponce Medical School Foundation Inc./CAIMED Center, Ponce, Puerto Rico|Fundación de Investigación de Diego, San Juan, Puerto Rico|San Juan Hospital Research Unit, San Juan, Puerto Rico|Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03110770,0,0
42,43,NCT03922594,Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia,,Recruiting,No Results Available,Microcephaly|Congenital Infection,Diagnostic Test: Differential diagnosis for infectious causes of microcephaly,"Incidence of microcephaly (per 10,000 live births)|Proportion of microcephaly attributable to ZIKV|Proportion of microcephaly linked to other infectious etiologies",Institut Pasteur|Centre Pasteur du Cameroun|Guangzhou Women and Children's Medical Center|Institut Pasteur de Côte d'Ivoire|Institut Pasteur Ho Chi Minh City|Tu Du Hospital|Perinatal Society of Sri Lanka|University of Colombo|University of Lausanne|University of Lausanne Hospitals|The University of Hong Kong|Ministry of Health of Sri Lanka|Central Hospital Maternity|Essos Hospital Center|Guangzhou Baiyun Maternal and Child Health Hospital|General Hospital of Yopougon-Attie|General Hospital Abobo-Sud|Castle Street Hospital for Women|De Soyza Hospital for Women,All,up to 2 Days   (Child),,125.0,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ZIKA_2016-102,"May 20, 2019",June 2021,June 2021,"April 22, 2019",,"June 25, 2019","Central Hospital Maternity, Yaoundé, Cameroon|Essos Hospital Centre Maternity, Yaoundé, Cameroon|Guangzhou Women's and Children's Hospital, Guangzhou, China|General Hospital Abobo-Sud, Abidjan, Côte D'Ivoire|General Hospital of Yopougon-Attie, Abidjan, Côte D'Ivoire|Castle Street Hospital for Women, Colombo, Sri Lanka|De Soyza Hospital for Women, Colombo, Sri Lanka|Tu Du Hospital, Ho Chi Minh City, Vietnam",,https://ClinicalTrials.gov/show/NCT03922594,0,0
43,44,NCT03037164,INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections,RedeS,Recruiting,No Results Available,Anemia,Device: INTERCEPT Blood System for Red Blood Cells|Device: Conventional (Control),Adjusted hemoglobin increment averaged over multiple transfusions|Adverse Events|Treatment emergent antibodies|Adjusted hemoglobin consumption|Transfusion reactions|RBC allo-antigens|Mortality,Cerus Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLI 00126,"May 11, 2017","June 30, 2020","December 30, 2020","January 31, 2017",,"July 12, 2019","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|OneBlood, Orlando, Florida, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Menonita General Hospital, Aibonito, Puerto Rico|HIMA San Pablo Hospital, Caguas, Puerto Rico|San Juan Bautista School of Medicine Clinical Research Unit, Caguas, Puerto Rico|Banco de Sangre de Servicios Mutuos, Inc. (BSSM), Guaynabo, Puerto Rico",,https://ClinicalTrials.gov/show/NCT03037164,0,0
44,45,NCT02887482,Study of GLS-5700 in Dengue Virus Seropositive Adults,,Completed,No Results Available,Healthy|Zika,Biological: GLS-5700|Biological: Placebo,Mean change from baseline in safety laboratory measures|Incidence of solicited adverse events after vaccination|Incidence of unsolicited adverse events after vaccination|Incidence of serious adverse events|Binding antibody titers to Zika envelope|Neutralizing antibody response against Zika virus|T cell response|Mean change from baseline for safety measures and adverse events,"GeneOne Life Science, Inc.|Inovio Pharmaceuticals",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,160.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Zika-002,August 2016,October 2017,June 2018,"September 2, 2016",,"December 5, 2018","Clinical Research of Puerto Rico, San Juan, Puerto Rico|Fundacion De Investigation, San Juan, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02887482,0,0
45,46,NCT01386424,Screening for LID Clinical Studies Unit Healthy Volunteer Protocols,,Recruiting,No Results Available,Zika|Influenza,,Find Healthy volunteers for research,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",,5000.0,NIH,Observational,Observational Model: Other|Time Perspective: Prospective,110183|11-I-0183,"July 20, 2011",,,"July 1, 2011",,"February 20, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01386424,0,0
46,47,NCT03055585,Applying Wolbachia to Eliminate Dengue,AWED,Recruiting,No Results Available,Dengue|Zika Virus Infection|Chikungunya Fever,Biological: Wolbachia-infected Aedes aegypti mosquitoes|Other: standard practice dengue control,Dengue incidence rate ratio in Wolbachia-treated versus untreated clusters|Zika incidence rate ratio in Wolbachia-treated versus untreated clusters|Chikungunya incidence rate ratio in Wolbachia-treated versus untreated clusters,Gadjah Mada University|Monash University|The Tahija Foundation,All,"3 Years to 45 Years   (Child, Adult)",Not Applicable,10000.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,UGM_KE/FK/105/EC,"November 8, 2017",December 2019,December 2019,"February 16, 2017",,"June 4, 2018","Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, DIY, Indonesia",,https://ClinicalTrials.gov/show/NCT03055585,0,0
47,48,NCT02741882,Zika and Microcephaly: Case-control Study,,Completed,No Results Available,Microcephaly,Other: Questionary,Zika virus infection clinical outcomes during pregnancy|zika virus serology|Chikungunya virus serology|Dengue virus serology,Laboratório Sabin,Female,"16 Years and older   (Child, Adult, Older Adult)",,110.0,Industry,Observational,Observational Model: Case-Control|Time Perspective: Retrospective,Zika and microcephaly,February 2016,August 2016,February 2017,"April 18, 2016",,"February 23, 2017","Sabin laboratory, Brasilia, Distrito Federal, Brazil",,https://ClinicalTrials.gov/show/NCT02741882,0,0
48,49,NCT01099852,Cohort of Patients Infected by an Arbovirus,CARBO,Recruiting,No Results Available,Fever|Dengue|Chikungunya|Zika Virus,Other: biological sample collection|Other: quality of life questionnaire EuroQol®|Other: Health Assessment Questionnaire - MDHAQ and RAPID3,"Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.|Specific complications: Onset of hemorrhagic fever (dengue) Onset of encephalitis or neurological disorders (West Nile virus, Japanese encephalitis, Zika virus) Onset of chronic form (Chikungunya)","University Hospital Center of Martinique|Institut National de la Santé Et de la Recherche Médicale, France|Clinique Antilles-Guyane",All,"Child, Adult, Older Adult",,1377.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,09/B/08,June 2010,July 2021,July 2021,"April 8, 2010",,"July 24, 2019","Hôpital Bichat-Claude Bernard, Paris, France|CH André Rosemond, Cayenne, French Guiana|CHU de Pointe à Pitre/Abymes, Pointe à Pitre, Guadeloupe|Centre Hospitalier Universitaire de Martinique, Fort-de-France, Martinique",,https://ClinicalTrials.gov/show/NCT01099852,0,0
49,50,NCT03631719,"Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia",WMP-COL,Recruiting,No Results Available,Dengue|Chikungunya Virus Infection|Zika Virus Infection,Biological: Wolbachia-carrying Ae.aegypti mosquitoes,Dengue cases notified to surveillance system|Virologically-confirmed dengue|IgM test positive for dengue|Severe dengue cases|Zika cases notified to surveillance system|Chikungunya cases notified to surveillance system|Spatial analysis|Virologically-confirmed chikungunya infection|Virologically-confirmed Zika infection,Universidad de Antioquia|Monash University|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation|Wellcome Trust,All,"3 Years and older   (Child, Adult, Older Adult)",,500.0,Other|U.S. Fed,Observational,Observational Model: Case-Control|Time Perspective: Prospective,PEC004_18|PECET-002,"October 25, 2017","December 31, 2019","December 31, 2019","August 15, 2018",,"February 25, 2019","Universidad de Antioquia, Medellín, Antioquia, Colombia",,https://ClinicalTrials.gov/show/NCT03631719,0,0
50,1,NCT04094727,Malaria High-Risk Populations in Namibia,,Enrolling by invitation,No Results Available,Malaria,Drug: Presumptive treatment with Artemether-lumefantrine (AL)|Other: Enhanced vector control,"Effective coverage of AL (presumptive treatment)|Effective coverage of IRS|Effective coverage of LLIN|Prevalence of infection measured by polymerase chain reaction (PCR)|Odds of symptomatic malaria associated with receiving each intervention|Total confirmed outpatient (OPD) malaria case incidence by health facility, stratified by HRP status|Malaria seroprevalence in HRPs|Test positivity rates from RACD|Entomological Indicators|Intervention acceptability as evaluated by participation rate|Intervention acceptability as evaluated by qualitative assessment|Cost effectiveness|Adherence to presumptive treatment intervention as evaluated by pill count|Self-reported compliance to LLIN and topical repellents.|HRP population size|HRP movement patterns","University of California, San Francisco|University of Namibia|Ministry of Health and Social Services, Namibia|University of Texas Southwestern Medical Center|University of Notre Dame|London School of Hygiene and Tropical Medicine",All,"6 Months and older   (Child, Adult, Older Adult)",Phase 4,3500.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Malaria HRP in Namibia,"October 31, 2019","May 31, 2020","May 31, 2020","September 19, 2019",,"November 13, 2019","University of Namibia, Multidisciplinary Research Centre, Windhoek, Namibia",,https://ClinicalTrials.gov/show/NCT04094727,1,1
51,2,NCT03334747,Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.,,Recruiting,No Results Available,Malaria,Drug: KAE609|Drug: Coartem,At least 2 CTCAE grades increase from baseline in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the 4 week study period|Polymerase Chain Reaction (PCR) corrected Clinical and Parasitological Cure|Recrudescence|Parasite Clearance Time|Proportion of patients with parasitaemia|Maximum Peak Observed Concentration (Cmax)|Area under the curve (AUC)|Time after administration of a drug when the maximum plasma concentrations is reached (Tmax)|Half-life (T½)|Uncorrected Adequate Clinical and Parasitological Response|Fever Clearance Time,Novartis Pharmaceuticals|Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,210.0,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CKAE609A2202,"November 16, 2017","November 25, 2019","April 30, 2020","November 7, 2017",,"January 27, 2020","Novartis Investigative Site, Lambarene, Gabon|Novartis Investigative Site, Kintampo, Ghana|Novartis Investigative Site, Navrango, Ghana|Novartis Investigative Site, Bamako, Mali|Novartis Investigative Site, Sotuba, Mali|Novartis Investigative Site, Kigali, Rwanda|Novartis Investigative Site, Bushenyi, Uganda|Novartis Investigative Site, Kampala, Uganda|Novartis Investigative Site, Tororo, Uganda",,https://ClinicalTrials.gov/show/NCT03334747,1,1
52,3,NCT02694874,Rosiglitazone Adjunctive Therapy for Severe Malaria in Children,ROSI,Recruiting,No Results Available,Malaria,Drug: Rosiglitazone|Drug: Placebo,"Change in serum Ang-2 levels in the first 96 hours of hospital admission.|Time to clinical recovery|Time to parasitological recovery|Mortality|Blood lactate levels, assessed at admission, every 12h for 24 hours then daily for Blood lactate levels|Change in levels of biomarkers of host response|Blood glucose levels|Cardiac effects|Biochemical and hematological parameters|AE/SAE|Neurocognitive outcomes","Centro de Investigacao em Saude de Manhica|University Health Network, Toronto|Barcelona Institute for Global Health",All,12 Months to 12 Years   (Child),Not Applicable,210.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROSI_v03_22072015,February 2016,June 2020,December 2020,"March 1, 2016",,"October 1, 2019","Centro de Investigação em Saude da Manhiça, Manhiça, Maputo, Mozambique",,https://ClinicalTrials.gov/show/NCT02694874,1,1
53,4,NCT02149550,Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains,,Completed,No Results Available,Malaria,Other: NF135 n=5|Other: NF135 n=2|Other: NF135 n=1|Other: NF166 n=5|Other: NF166 n=2|Other: NF166 n=1,Proportion of subjects in each group who develop patent parasitaemia as assessed by QRT-PCR|Time to patent parasitaemia in each group as assessed by QRT-PCR|Magnitude of first peak of parasitaemia in each group as assessed by QRT-PCR|Frequency of malaria-related symptoms and signs in each group,Radboud University|Havenziekenhuis,All,18 Years to 35 Years   (Adult),Not Applicable,24.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",BMGF2a,August 2014,October 2014,November 2014,"May 29, 2014",,"November 24, 2014","UMC St Radboud, Nijmegen, Netherlands|Havenziekenhuis, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT02149550,1,1
54,5,NCT04102592,"Getting Malaria ""Off the Back"" of Women and Children in Western Uganda",,Recruiting,No Results Available,Malaria,Other: Permethrin-treated Lesu (baby wrap)|Other: Untreated Lesu (baby wrap),Reported change in frequency of use of lesu|Incidence of symptomatic malaria episodes among children|Incidence of P. falciparum malaria parasitemia among children|Change in mosquito salivary antigen response among children|Change in mosquito salivary antigen response among mothers|Changes in hemoglobin levels among children|Changes in hemoglobin levels among mothers,"University of North Carolina, Chapel Hill|Conservation, Food, and Health Foundation",Female,18 Years to 50 Years   (Adult),Not Applicable,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,18-1819|IGHID 11829,"October 28, 2019",December 2020,December 2020,"September 25, 2019",,"November 14, 2019","Bugoye Level III Health Centre, Bugoye, Kasese, Uganda",,https://ClinicalTrials.gov/show/NCT04102592,1,1
55,6,NCT04072302,Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model,,Completed,No Results Available,Malaria,Drug: KAF156|Drug: Placebo,"Number of subjects with parasitemia after single dose oral administration of KAF156 either prior to, or following, exposure to P. falciparum sporozoite-infected mosquitoes|Relationship between pharmacokinetics (i.e., Maximum Plasma Concentration [Cmax], Area Under Curve [AUC]) of KAF156 and number of subjects with parasitemia, after oral administration of single descending doses of KAF156 in healthy subjects with CHMI|Number of subjects with adverse events, serious adverse events, and death|Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)|Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Pharmacokinetics of KAF156: Area under teh plasma concentration-time curve from time zero to time 24 h (AUC0-24)|Pharmacokinetics of KAF156: Terminal elimination half life (T1/2)|Pharmacokinetics of KAF156: Apparent systemic clearance from plasma following oral administration (CL/F)|Pharmacokinetics of KAF156: Apparent volume of distribution during the terminal phase following oral administration (Vz/F)|Pharmacokinetics of KAF156: Observed maximum plasma concentration (Cmax)|Pharmacokinetics of KAF156: Time to reach the maximum concentration (Tmax)|Parasite growth Kinetics by qRT-PCR",Novartis Pharmaceuticals|Novartis,Male,18 Years to 40 Years   (Adult),Phase 1,86.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",CKAF156X2202,"September 15, 2014","November 29, 2017","November 29, 2017","August 28, 2019",,"August 28, 2019","Novartis Investigative Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT04072302,1,1
56,7,NCT01939886,Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2),TRANSACT2,Completed,No Results Available,Malaria,Drug: Mefloquine - Artesunate|Drug: Artemether-lumefantrine combination,the number of participants with clinical and parasitological treatment failure after treatment artemether-lumefantrine (AL) and mefloquine-artesunate MQ-AS|the number of individuals with gametocytes after treatment with AL or MQ-AS,"London School of Hygiene and Tropical Medicine|Kilimanjaro Christian Medical Centre, Tanzania|Radboud University|European Union",All,6 Months to 10 Years   (Child),Phase 3,219.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",TRANSACT 2,April 2013,November 2013,November 2013,"September 11, 2013",,"November 28, 2013","St. Jude's Clinic, ICIPE Thomas Odhiambo Campus, Mbita, Nyanza, Kenya",,https://ClinicalTrials.gov/show/NCT01939886,1,1
57,8,NCT03594084,Malaria in Strasbourg University Hospital,ACMUS,Recruiting,No Results Available,Malaria,,Study of clinical characteristics of imported malaria in people originated from endemic areas hospitalized at Strasbourg University Hospital from 2017 to 2018.,"University Hospital, Strasbourg, France",All,"Child, Adult, Older Adult",,70.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,7084,"August 1, 2018",August 2019,August 2019,"July 20, 2018",,"September 17, 2018","Service de Maladies Infectieuses et Tropicales, Strasbourg, France",,https://ClinicalTrials.gov/show/NCT03594084,1,1
58,9,NCT02153996,Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States,,Terminated,No Results Available,Malaria,,Estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure.|Compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to age and sex matched individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.,National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC),All,"18 Years to 65 Years   (Adult, Older Adult)",,3.0,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,140121|14-I-0121,"May 15, 2014","March 15, 2016","March 15, 2016","June 3, 2014",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02153996,1,1
59,10,NCT02315690,Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland,fMDA,Completed,No Results Available,Malaria,Drug: dihydroartemisinin-piperaquine (DHAp)|Procedure: reactive case detection,Incidence of malaria cases|Seroprevalence|Prevalence|Coverage|Adherence|Safety related to DHAp|Acceptability|Cost,"University of California, San Francisco|Ministry of Health, Swaziland|Clinton Health Access Initiative, Nigeria|University of Texas",All,"Child, Adult, Older Adult",Phase 3,4000.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Swaziland fMDA,September 2015,July 2017,July 2017,"December 12, 2014",,"October 30, 2017","Swaziland Ministry of Health, Mbabane, Swaziland",,https://ClinicalTrials.gov/show/NCT02315690,1,1
60,11,NCT01624337,Malaria Prevention Cambodia,MPC,Terminated,No Results Available,Malaria,Drug: DHA-piperaquine|Drug: placebo,Protective efficacy|Cardiac safety of piperaquine as determined by QT interval prolongation,"Armed Forces Research Institute of Medical Sciences, Thailand|National Centre for Parasitology, Entomology and Malaria Control, Cambodia|Royal Cambodian Armed Forces|United States Army Medical Materiel Development Activity",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,231.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",WRAIR # 1849|A-17057,May 2012,August 2014,June 2015,"June 20, 2012",,"July 12, 2016","Anlong Veng Referral Hospital, Anlong Veng, Oddar Meancheay, Cambodia",,https://ClinicalTrials.gov/show/NCT01624337,1,1
61,12,NCT02174978,Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults,,Completed,No Results Available,Malaria,Biological: FMP012 with AS01B adjuvant system|Other: P falciparum Controlled Human Malaria Infection (CHMI),Number of solicited adverse events (AE)|Number of unsolicited AEs|Occurrence of serious adverse events (SAE) at any time during the study period (enrollment to final follow-up visit)|Anti-FMP012 antibody titers in serum|Time to parasitemia by blood smear after the P falciparum challenge,U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID)|Military Infectious Diseases Research Program (MIDRP)|GlaxoSmithKline,All,18 Years to 50 Years   (Adult),Phase 1,39.0,U.S. Fed|Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,S-14-02,August 2014,June 2015,October 2015,"June 26, 2014",,"October 13, 2017","Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02174978,1,0
62,13,NCT01231880,School Based Malaria Control in Ugandan Schoolchildren,SBMC,Completed,No Results Available,Malaria,Drug: Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Drug: Monthly IPT using DP|Drug: Placebo given every month,Risk of Clinical Malaria|Cognitive function tests|Risk of parasitemia|Risk of hospital admissions|Risk of adverse events|School performance|Prevalence of anemia,Makerere University|Bill and Melinda Gates Foundation,All,6 Years to 14 Years   (Child),Phase 3,740.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",MCDC-SBMC,February 2011,September 2012,September 2012,"November 1, 2010",,"May 23, 2013","Mulanda Sub-district, Tororo, Uganda",,https://ClinicalTrials.gov/show/NCT01231880,1,1
63,14,NCT01443130,Chloroquine for Malaria in Pregnancy,,Completed,Has Results,Malaria,Drug: Chloroquine|Drug: Sulfadoxine-pyrimethamine,"Incidence of Placental Malaria Infection Based on Histology|Incidence of Placental Malaria by Placental Impression Smear|Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter)|Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl)|Incidence of Stillbirth|Incidence of Miscarriage|Incidence of Preterm Delivery|Infant Mortality Rate to 14 Weeks of Age|Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams)|Incidence of Intrauterine Growth Restriction (IUGR)|Incidence of Active Placental Malaria Infection|Incidence of Malaria Infection, All Species.|Incidence of Clinical Malaria, All Species|Incidence of Infection in the Fetal Circulation",National Institute of Allergy and Infectious Diseases (NIAID),Female,"up to 99 Years   (Child, Adult, Older Adult)",Phase 3,900.0,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,09-0112|4R01AI104702-04,February 2012,October 2014,January 2015,"September 29, 2011","October 29, 2015","December 28, 2016","Blantyre Malaria Project - Queen Elizabeth Central Hospital, Blantryre, Blantyre, Malawi",,https://ClinicalTrials.gov/show/NCT01443130,1,1
64,15,NCT03387631,Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania,TES2016,Completed,No Results Available,Uncomplicated Malaria,Drug: Artemether-Lumefantrine,Cure rates as per WHO protocol,"National Institute for Medical Research, Tanzania",All,6 Months to 10 Years   (Child),,344.0,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,NIMRTanzania,April 2016,September 2016,September 2016,"January 2, 2018",,"January 2, 2018",,,https://ClinicalTrials.gov/show/NCT03387631,1,1
65,16,NCT02394522,Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM),SR-M-ZM,Withdrawn,No Results Available,Malaria,Device: Spatial Repellent product with active ingredient (SHIELD)|Device: Active Ingredient|Device: Spatial Repellent product without active ingredient (SHIELD),Malaria Incidence,"University of Notre Dame|Ministry of Health, Zambia|Macha Research Trust, Zambia|Johns Hopkins University",All,6 Months to 59 Months   (Child),Not Applicable,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SR-M-Zm,March 2016,April 2016,April 2016,"March 20, 2015",,"October 6, 2016","Macha Research Trust, Macha, Choma, Zambia",,https://ClinicalTrials.gov/show/NCT02394522,1,1
66,17,NCT02294201,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya,SR-M-KEN,Withdrawn,No Results Available,Malaria,Device: Spatial Repellent product with active ingredient|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD),Malaria Incidence,University of Notre Dame|Centers for Disease Control and Prevention|Kenya Medical Research Institute,All,6 Months to 59 Months   (Child),Not Applicable,0.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SR-M-KEN,June 2016,July 2016,July 2016,"November 19, 2014",,"October 6, 2016","Kemri-Crc, Kisumu, Kenya",,https://ClinicalTrials.gov/show/NCT02294201,1,1
67,18,NCT02294188,Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia,SR-M-IDR,Completed,No Results Available,Malaria,Device: Spatial Repellent product with active ingredient (SHIELD)|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD),Malaria Incidence,"University of Notre Dame|Ministry of Health, Indonesia",All,6 Months to 59 Months   (Child),Not Applicable,1519.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SR-M-IDR,May 2015,"April 15, 2018","April 15, 2018","November 19, 2014",,"May 3, 2018","Eijkman Institute for Molecular Biology, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT02294188,1,1
68,19,NCT02294214,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania,SR-M-Tz,Withdrawn,No Results Available,Malaria,Device: Spatial Repellent product with active ingredient|Device: Active ingredient|Device: Spatial Repellent product without active ingredient (SHIELD),Malaria Incidence,University of Notre Dame|Ifakara Health Institute,All,6 Months to 59 Months   (Child),Not Applicable,0.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",SR-M-TZ,February 2016,April 2016,April 2016,"November 19, 2014",,"October 6, 2016","Ifakara Health Institute, Bagamoyo, Tanzania",,https://ClinicalTrials.gov/show/NCT02294214,1,1
69,20,NCT01627951,Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection,TIP3,Completed,No Results Available,Malaria,Other: NF54|Other: NF135|Other: NF166,"Difference in kinetics of infection between groups infected with NF54, NF133 and NF166, as defined by a mathematical model that takes into account multiple measurements of parasitaemia|Difference in time till thick smear positivity between groups infected with NF54, NF135 and NF166|Difference in duration or peak height of parasitaemia between groups infected with NF54, NF135 and NF166|Difference in frequency of malaria-related symptoms and signs between groups infected with NF54, NF135 and NF166|Difference in induced immunological responses between groups infection with NF54, NF135 and NF166",Radboud University|Havenziekenhuis,All,18 Years to 35 Years   (Adult),Not Applicable,15.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",TIP3,August 2012,October 2012,November 2012,"June 26, 2012",,"November 27, 2012","UMC St Radboud, Nijmegen, Netherlands|Havenziekenhuis, Rotterdam, Netherlands",,https://ClinicalTrials.gov/show/NCT01627951,1,1
70,21,NCT04176029,Lung Ultrasound in Children With Severe Malaria,LUSiSM,Not yet recruiting,No Results Available,Severe Malaria,Device: lung ultrasound,Proportion of children diagnoses|Proportion of children that fulfill the criteria for a new pulmonary diagnosis >6 hours from admission.|Median lung ultrasound score|Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema.|Hospital mortality and 30 days mortality,University of Oxford|Mahidol Oxford Tropical Medicine Research Unit|University of Kinshasa,All,1 Year to 14 Years   (Child),,171.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MAL19008,"December 1, 2019","August 1, 2020","November 1, 2020","November 25, 2019",,"November 25, 2019","The Maluku District Hospital, Kinshasa, Congo, The Democratic Republic of the",,https://ClinicalTrials.gov/show/NCT04176029,1,1
71,22,NCT03341754,"Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults",,Recruiting,No Results Available,Malaria,Biological: D/ChAd63-CA|Biological: D/ChAd63-CAT|Other: Infectivity Control (IC) Group,Occurrence of Serious Adverse Events|Occurrence of Abnormal Physical Symptoms (Clinical Abnormalities)|Occurrence of Abnormal Laboratory Values|Occurrence of Any Serious Adverse Events Throughout the Study Period|Vaccine Efficacy Determined by Time to Development of Parasitemia|Measurement of Antibody Titers Against Sporozoite and Erythrocyte Stage Parasites|Measure of correlation between pre-immunization HuAd5 neutralizing antibody titers and the protective efficacy against CHMI and humoral and cellular immune responses of the 2 prime-boost regimens|Comparison of Immunogenicity of the 2 Vaccine Regimens,U.S. Army Medical Research and Development Command|University of Oxford|Walter Reed Army Institute of Research (WRAIR)|United States Agency for International Development (USAID)|Naval Medical Research Center,All,18 Years to 50 Years   (Adult),Phase 1,52.0,U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,S-14-07|NMRC.2016.0006|NavOx,"September 15, 2018","December 30, 2019",October 2020,"November 14, 2017",,"October 26, 2018","NMRC Clinical Trials Center, Bethesda, Maryland, United States|WRAIR, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03341754,1,1
72,23,NCT01190202,Epidemiology Study of Malaria Transmission Intensity in Africa,,Completed,No Results Available,Malaria,Procedure: Blood sampling|Procedure: Assessment of body temperature,Occurrence of Plasmodium falciparum parasitemia during the first year|Occurrence of P. falciparum parasitemia during the second year|Occurrence of P. falciparum parasitemia during the third year|Occurrence of P. falciparum parasitemia during the fourth year|Occurrence of P. falciparum parasitemia|Occurrence of anemia|Occurrence of anti-malarial therapy|Occurrence of fever|Occurrence of each risk factor|Occurrence of malaria prevention measures|Occurrence of other Plasmodium parasitemia,GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI),All,"6 Months and older   (Child, Adult, Older Adult)",,13380.0,Industry|Other,Observational,Time Perspective: Cross-Sectional,114001,March 2011,December 2013,December 2013,"August 27, 2010",,"September 30, 2015","GSK Investigational Site, Ouagadougou 01, Burkina Faso|GSK Investigational Site, Lambaréné, Gabon|GSK Investigational Site, Kintampo, Ghana|GSK Investigational Site, Kumasi, Ghana|GSK Investigational Site, Kisumu, Kenya|GSK Investigational Site, Lilongwe, Malawi|GSK Investigational Site, Dar-es-Salaam, Tanzania|GSK Investigational Site, Korogwe, Tanga, Tanzania",,https://ClinicalTrials.gov/show/NCT01190202,1,1
73,24,NCT02793622,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,PROMOTE-BC3,"Active, not recruiting",No Results Available,Malaria,Drug: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Drug: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy,Proportion of women who deliver with a composite adverse birth outcome|Incidence of malaria in infants|Comparison of estimates of gestational age at birth using two methods|Prevalence of placental malaria by histopathology|Prevalence of placental parasitemia|Prevalence of maternal malaria|Incidence of adverse events in pregnant women|Prevalence of anemia in pregnant women|Prevalence of anemia in infants|Prevalence of asymptomatic parasitemia in pregnant women|Prevalence of asymptomatic parasitemia in infants|Incidence of complicated malaria in infants|Incidence of hospital admissions in infants|Infant mortality rate,"University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Bill and Melinda Gates Foundation",Female,"16 Years and older   (Child, Adult, Older Adult)",Phase 3,782.0,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",PROMOTE-BC3,September 2016,June 2019,June 2019,"June 8, 2016",,"July 11, 2018","IDRC - Tororo Research Clinic, Tororo, Uganda",,https://ClinicalTrials.gov/show/NCT02793622,1,1
74,25,NCT02658253,Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults,PRIMALVAC,Completed,No Results Available,Malaria,Biological: PRIMVAC|Biological: GLA-SE|Biological: Alhydrogel|Biological: Placebo,Proportion of volunteers with treatment-related adverse events as assessed by FDA scale and the INYVAX EC FP7 Brighton Collaboration Foundation|Proportion of volunteer with at least one Serious Adverse Event Following Immunization (SAEFI) for the entire duration of the study|Proportion of volunteer with at least one of Adverse Event Following Immunization (AEFI) measured until 1 month post-dose 3|Proportion of volunteer with at least one Adverse Event Following Immunization (AEFI) measured between M3 and the end of the study (only phase Ia)|Variation in humoral immune response to the vaccine antigen assessed by ELISA|Cellular immune responses to the vaccine antigen by Elispot|Cellular immune responses to the vaccine antigen by FACS,"Institut National de la Santé Et de la Recherche Médicale, France|EVI Industries, Inc.|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|National Center for Research and Training on Malaria|EUCLID",Female,18 Years to 35 Years   (Adult),Phase 1,68.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",C14-60|2015-002246-31,January 2016,"September 19, 2018","February 21, 2019","January 18, 2016",,"November 29, 2019","CNRFP, Ouagadougou, Burkina Faso|CIC 1417, Paris, France",,https://ClinicalTrials.gov/show/NCT02658253,1,0
75,26,NCT01464138,Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children,,Completed,No Results Available,Malaria,Drug: Fosmidomycin and Clindamycin co-administration,Day 28 cure rate >95%|Day 7 cure rate of 100%|Parasite Clearance Time|Fever Clearance Time,Jomaa Pharma GmbH|Fundacio Clinic|Hospital Clinic of Barcelona,All,6 Months to 3 Years   (Child),Phase 2,52.0,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JP012,September 2010,September 2011,September 2011,"November 3, 2011",,"November 3, 2011","Centro de Investigacao em Saude da Manhica, Maputo, Mozambique",,https://ClinicalTrials.gov/show/NCT01464138,1,1
76,27,NCT02298140,Providers' Compliance to Malaria Treatment,(PCMT),Unknown status,No Results Available,Malaria,Other: SMS reminders,Provider Compliance|Number of fever patients who received diagnostic test|Number of confirmed malaria patients treated with recommended antimalaria|Number of malaria patients who received correct dose of ACT|Number of patients with a negative malaria test who did not receive antimalaria|Number of afebrile patients who are tested for malaria|Number of patients who received counselling messages|Number of patients who completed antimalaria doses as instructed,Ifakara Health Institute|Swiss Tropical & Public Health Institute|KEMRI-Wellcome Trust Collaborative Research Program,All,"Child, Adult, Older Adult",Not Applicable,712.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,3245,November 2014,December 2015,December 2015,"November 21, 2014",,"August 3, 2015","Ifakara Health Institute, Rufiji, Pwani, Tanzania",,https://ClinicalTrials.gov/show/NCT02298140,1,1
77,28,NCT01805232,Intravenous Artesunate and Malaria,IVAS,Unknown status,No Results Available,Malaria,Drug: artesunate|Drug: Quinine,clearance of the parasite and fever,"University of Khartoum|University of Kassala, Sudan|Kassala|Sudan",All,"1 Year to 80 Years   (Child, Adult, Older Adult)",Phase 4,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,artesunate and malaria,March 2013,May 2013,July 2013,"March 6, 2013",,"March 6, 2013","Kassala, Kassala, Sudan",,https://ClinicalTrials.gov/show/NCT01805232,1,1
78,29,NCT03967054,Repeat Ivermectin Mass Drug Administrations for MALaria Control II,RIMDAMAL II,Recruiting,No Results Available,Malaria,Drug: Ivermectin|Drug: Placebo oral tablet,Malaria incidence|Adverse Events|Blood fed mosquito mortality|Entomological inoculation rate|Human antibody responses to an Anopheles salivary gland peptide|Plasmodium prevalence|Plasmodium parasitemia|Plasmodium multiplicity of infection|Plasmodium molecular force of infection,Brian Foy|Yale University|Institut de Recherche en Sciences de la Sante|Radboud University|PATH|Colorado State University,All,"Child, Adult, Older Adult",Phase 3,4700.0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",18-1803H,"July 13, 2019",December 2020,July 2023,"May 30, 2019",,"August 28, 2019","Institut de Recherche en Sciences de la Sante, Diebougou, Sud-Ouest, Burkina Faso",,https://ClinicalTrials.gov/show/NCT03967054,1,1
79,30,NCT01323972,Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children,,Completed,Has Results,Malaria,Biological: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049),"Anti-Circumsporozoite (Anti-CS) Antibody Titers|Anti-hepatitis B (Anti-HB) Antibody Concentrations|Number of Subjects With Any and Grade 3 Solicited Local Symptoms|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects With Unsolicited Adverse Events|Number of Subjects With Serious Adverse Events",GlaxoSmithKline|The PATH Malaria Vaccine Initiative (MVI),All,5 Months to 17 Months   (Child),Phase 3,327.0,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",113398,"May 16, 2011","November 22, 2011","May 4, 2012","March 28, 2011","August 7, 2017","August 17, 2018","GSK Investigational Site, Enugu, Nigeria|GSK Investigational Site, Jos, Nigeria",,https://ClinicalTrials.gov/show/NCT01323972,1,1
80,31,NCT03824236,"A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults",,Completed,No Results Available,Malaria,"Biological: RTS,S/AS01E (SB257049)","Number of subjects reporting P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge (in all study groups versus infectivity controls)|Time-to-onset of P. falciparum parasitemia (defined by a positive blood slide) following sporozoite challenge in all study groups|Anti-Circumsporozoite (Anti-CS) protein of P. falciparum repeat region antibody concentrations in the booster vaccination groups|Anti-hepatitis B antigen (Anti-HBs) Igtot antibody concentrations in the booster vaccination groups|Number of subjects with solicited local Adverse Events (AEs) in the booster vaccination groups|Number of subjects with solicited general AEs in the booster vaccination groups|Number of subjects with unsolicited AEs following vaccination in the booster vaccination groups|Number of subjects with AEs after challenge in all study groups|Number of subjects with AEs of specific interest in all study groups|Number of subjects with SAEs (all, fatal, related to investigational vaccine) in all study groups|Number of subjects with abnormal laboratory values in the booster vaccination groups|Number of subjects with abnormal laboratory values in the infectivity control subjects",GlaxoSmithKline|PATH,All,18 Years to 55 Years   (Adult),Phase 2,61.0,Industry|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,209003|17337,"February 5, 2019","April 30, 2019","September 26, 2019","January 31, 2019",,"October 4, 2019","GSK Investigational Site, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT03824236,1,0
81,32,NCT03035305,Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali,,Completed,No Results Available,Malaria,Dietary Supplement: Lipid-based Nutrient Supplement (LNS)|Drug: Seasonal malaria chemoprevention,Confirmed malaria case|Fever case|Global acute malnutrition case|Moderate acute malnutrition case|Severe acute malnutrition case|Medical referral case,"Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale, France|Alliance médicale contre le paludisme, Mali|Programme national de lutte contre le paludisme, Mali|United States Agency for International Development (USAID)|European commission for humanitarian office|Ministry of health, Mali",All,6 Months to 59 Months   (Child),Not Applicable,36717.0,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,SMC LNS Mali,August 2016,November 2016,November 2016,"January 30, 2017",,"January 30, 2017","Amcp/Alima, Kolokani Circle, Koulikoro region, Mali",,https://ClinicalTrials.gov/show/NCT03035305,1,1
82,33,NCT01753323,"Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",,Completed,Has Results,Malaria,Drug: KAF156,"Time to Parasite Clearance|28-day Cure Rate - Part 2|Area Under the Curve (AUC)0-24h - Part 1|Maximum Concentration (Cmax) - Part 1|Time to Maximum Concentration (Tmax) - Part 1|Area Under the Curve (AUC)Last - Part 1|Area Under the Curve (AUC)Inf - Part 1|Half-life (T1/2) - Part 1|Clearance (CL/F ) - Part 1|Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1|Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1|AUC0-24h - Part 2|AUC0-48h - Part 2|AUClast - Part 2|AUCinf - Part 2|Cmax - Part 2|Tmax - Part 2|T1/2 - Part 2|CL/F - Part 2|Vz/F - Part 2",Novartis Pharmaceuticals|Novartis,All,20 Years to 60 Years   (Adult),Phase 2,43.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CKAF156X2201,March 2013,August 2014,August 2014,"December 20, 2012","August 19, 2015","June 7, 2018","Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Srisaket, Thailand|Novartis Investigative Site, Tak, Thailand|Novartis Investigative Site, Tak, Thailand|Novartis Investigative Site, Hanoi, Vietnam",,https://ClinicalTrials.gov/show/NCT01753323,1,1
83,34,NCT04020653,A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria,,Not yet recruiting,No Results Available,Malaria,Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|Drug: Sodium ferrous citrate (SFC) 472 mg QD|Drug: Artemisinin-based combination (ACT)|Drug: Placebo|Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|Drug: Sodium ferrous citrate (SFC) 236 mg BID,Number of patients with adverse events|Cure rate on Day 28|Parasite Clearance Time|Fever Reduction Time|Gametocyte Clearance Time|Change in inflammatory parameter: C-reactive protein|Change in inflammatory parameter: interleukin-6|Change in inflammatory parameter: tumor necrosis factor (TNF)-alpha|Change in iron metabolism: Serum iron|Change in iron metabolism: Hepcidin|Change in iron metabolism: total iron binding capacity (TIBC)|Change in iron metabolism: unsaturated iron binding capacity (UIBC),"Neopharma Japan Co., Ltd.|Parexel",All,18 Years to 60 Years   (Adult),Phase 2,75.0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NPJ005-MAL-0122,"September 6, 2019","May 31, 2020","September 30, 2020","July 16, 2019",,"July 16, 2019",,,https://ClinicalTrials.gov/show/NCT04020653,1,1
84,35,NCT03689036,Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimination,,Recruiting,No Results Available,Malaria,,Risk factors for residual malaria infection and disease|Genetic characterization of locally circulating malaria parasites over space and time|Estimating the impact of interventions to control and eliminate malaria.,Oswaldo Cruz Foundation|University of Sao Paulo,All,"3 Months and older   (Child, Adult, Older Adult)",,2000.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,DMID 17-0037-A,"April 2, 2018","October 31, 2023","July 31, 2024","September 28, 2018",,"September 28, 2018","Marcelo Urbano Ferreira, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03689036,1,1
85,36,NCT02532049,A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313,,Completed,No Results Available,Malaria,Biological: ChAd63 Pfs25-IMX313|Biological: MVA Pfs25-IMX313,"Number of Adverse Events|Immunogenicity of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime.|Ex-vivo efficacy of ChAd63 Pfs25-IMX313 when administered to healthy volunteers alone, and with MVA Pfs25-IMX313 in a prime-boost regime. The functional activity of the vaccine induced antibodies will be tested using membrane-feeding assays.",University of Oxford,All,18 Years to 50 Years   (Adult),Phase 1,26.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,VAC062,"October 12, 2015","May 25, 2017","May 25, 2017","August 25, 2015",,"July 17, 2017","CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|NIHR Wellcome Trust Clinical Research Facility, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02532049,1,0
86,37,NCT02511353,Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study,IVERMAL,Completed,No Results Available,Malaria,Drug: ivermectin|Drug: placebo|Drug: dihydroartemisinin-piperaquine,Mosquito survival|Number of patients with malaria clinical and parasitological treatment response|Area under the plasma concentration versus time curve (AUC) of ivermectin|Area under the plasma concentration versus time curve (AUC) of piperaquine|Peak plasma Concentration (Cmax) of ivermectin|Peak plasma Concentration (Cmax) of piperaquine|Tolerability as assessed by adverse events reported in a general toxicity questionnaire|CNS adverse events|Serious adverse events|Haemoglobin concentrations|QTc interval|Mydriasis quantitated by pupillometry,Liverpool School of Tropical Medicine|Kenya Medical Research Institute|Centers for Disease Control and Prevention,All,18 Years to 50 Years   (Adult),Phase 2,141.0,Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14.002|2775|6720,July 2015,July 2016,July 2016,"July 30, 2015",,"August 23, 2018","Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya",,https://ClinicalTrials.gov/show/NCT02511353,1,0
87,38,NCT01916954,Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy,ALN5P,Completed,No Results Available,Malaria,Drug: 3-day artemether-lumefantrine|Drug: 5-day artemether-lumefantrine,Pharmacokinetics measures|Tolerability and safety measures,University of Oxford|University of Kinshasa,Female,18 Years to 45 Years   (Adult),Phase 3,96.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALN5P,July 2013,March 2014,,"August 6, 2013",,"March 26, 2014","University of Kinshasa, Democratic Republic of Congo, Kinshasa, Congo",,https://ClinicalTrials.gov/show/NCT01916954,1,1
88,39,NCT01540474,"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults",,Completed,No Results Available,Malaria,Biological: Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological: Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE,Safety|AntiFMP-12 antibody titers in serum,U.S. Army Medical Research and Development Command|United States Agency for International Development (USAID)|IDRI,All,18 Years to 50 Years   (Adult),Phase 1,30.0,U.S. Fed|Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A-17085|WRAIR 1853,February 2012,October 2012,December 2012,"February 28, 2012",,"January 15, 2013","Clinical Trials Center, WRAIR, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01540474,1,1
89,40,NCT04230161,Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Rwanda,,Not yet recruiting,No Results Available,Malaria,Other: Standard long-lasting insecticidal net|Other: Chlorfenapyr insecticide treated net|Other: Indoor residual spraying,Cumulative malaria incidence|Vector species composition|Species-specific population densities|Biting behaviors|Estimated entomological inoculation rates|Insecticide resistance profile|Parasite prevalence in children 6 months or older,PATH|Rwanda Biomedical Centre|University of Rwanda|Liverpool School of Tropical Medicine,All,"6 Months and older   (Child, Adult, Older Adult)",,3669.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1409734-2,"January 13, 2020","September 1, 2022","December 31, 2022","January 18, 2020",,"January 18, 2020","Rwanda Biomedical Centre, Kigali, Rwanda",,https://ClinicalTrials.gov/show/NCT04230161,1,1
90,41,NCT03503058,"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria",,Not yet recruiting,No Results Available,Malaria,Biological: PfSPZ Vaccine|Biological: PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|Other: Normal Saline,The number of adverse events occurring after vaccination and placebo administration|The number of microscopy-confirmed first infections with Pf|The number of microscopy confirmed first infections with Pv in eastern Indonesia|The number of microscopy confirmed first infections with Pv after leaving eastern Indonesia|The number of PCR-confirmed first infections|The immune responses induced by vaccination compared to those induced by placebo administration|Associations between immune responses and protection among subjects receiving vaccine vs. placebo during the period from 10 days after arriving in eastern Indonesia through 10 days after leaving eastern Indonesia.|Associations between immune responses measured prior to the 24-week period of surveillance beginning after return to Java and the risk of relapse during that period.,Sanaria Inc.|Eijkman Oxford Clinical Research Unit|Indonesia University|Congressionally Directed Medical Research Programs,Male,18 Years to 55 Years   (Adult),Phase 2,420.0,Industry|Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",IDSPZV1,April 2020,April 2021,June 2021,"April 19, 2018",,"January 7, 2020","Department of Internal Medicine, Universitas Indonesia, Jakarta, Indonesia|Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia",,https://ClinicalTrials.gov/show/NCT03503058,1,0
91,42,NCT04157894,Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generated During Piloted New Net Distributions in Burkina Faso,,Recruiting,No Results Available,Malaria,Other: Standard long-lasting insecticidal net|Other: Chlorfenapyr insecticide treated net|Other: Piperonyl butoxide long-lasting insecticidal net,Cumulative malaria incidence|Vector species composition|Species-specific population densities|Biting behaviors|Estimated entomological inoculation rates|Insecticide resistance profile|Parasite prevalence in children 6-59 months,PATH|National Center for Research and Training on Malaria|Liverpool School of Tropical Medicine,All,"6 Months and older   (Child, Adult, Older Adult)",,6734.0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,1379279-2,"July 7, 2019","September 1, 2022","December 31, 2022","November 8, 2019",,"November 8, 2019","Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso",,https://ClinicalTrials.gov/show/NCT04157894,1,1
92,43,NCT02533336,The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania,DL,Terminated,No Results Available,Malaria,Drug: abamectin and fenpyroximate,Incidence of malaria parasitemia|Effectiveness of DL on anemia,"National Institute for Medical Research, Tanzania|Kilimanjaro Christian Medical Centre, Tanzania|London School of Hygiene and Tropical Medicine|Centers for Disease Control and Prevention|Brandeis University|United States Agency for International Development (USAID)",All,6 Months to 11 Years   (Child),Phase 3,4917.0,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,DL Project in Tanzania,"November 9, 2015","August 31, 2016","March 31, 2017","August 26, 2015",,"February 5, 2019","Muheza, Tanga, Muheza, Tanzania",,https://ClinicalTrials.gov/show/NCT02533336,1,1
93,44,NCT02878265,The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children,,Completed,No Results Available,Malaria,"Dietary Supplement: Vitamin A|Dietary Supplement: Vitamin A and ZInc|Dietary Supplement: Vitamin A , Zinc and Multivitamin",Incidence of clinical malaria attacks|Incidence of diarrhea attacks,University of Ghana|Kwame Nkrumah University of Science and Technology,Female,"Child, Adult, Older Adult",Phase 3,547.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,VAZ20016,November 2011,May 2012,December 2012,"August 25, 2016",,"August 25, 2016","Amoako, Accra, Ghana",,https://ClinicalTrials.gov/show/NCT02878265,1,1
94,45,NCT03568344,Community Access to Rectal Artesunate for Malaria,CARAMAL,"Active, not recruiting",No Results Available,Malaria,,Proportion of children <5 years with severe febrile illness seen by CHW/primary HF that resulted in death within 28 days|Proportion of children <5 years with severe febrile illness without parasites on day 28|Proportion of children <5 years with a recent history of fever (mild or severe) who attend CHW/primary HF|Proportion of children <5 years with severe febrile illness seen by CHW/primary HF who completed referral|Number of children <5 years with severe febrile illness who report directly to referral health facility|Proportion of children <5 years with severe febrile illness managed pre-referral according to guidelines|Proportion of children <5 years with severe febrile illness managed post-referral according to guidelines|Frequency of passively reported adverse events after RAS administration|Frequency of delayed haemolytic anaemia within 28 days after RAS administration|Proportion of trained and functional CHW and primary HF who provide QA RAS|Proportion of CHW/primary HF with RAS in stock|Proportion of referral health facilities that have the capacity to manage severe malaria in children in line with global guidance|Proportion of CHW/primary HF that received at least one supervisory visit in the past 3 months|Acceptability of pre-referral RAS among health workers|Acceptability of pre-referral RAS among caretakers|Total financial cost of managing severe case at community level. Marginal financial cost of adding RAS to the management|Financial cost of RAS interventions per death averted,"Swiss Tropical & Public Health Institute|UNITAID|UNICEF|Kinshasa School of Public Health|Akena Associates Ltd.|Clinton Health Access Initiative, USA|Makerere University",All,6 Months to 59 Months   (Child),,6032.0,Other,Observational,Observational Model: Other|Time Perspective: Prospective,P 001-17-1.2,"June 15, 2018","May 31, 2020","May 31, 2020","June 26, 2018",,"October 28, 2019","Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the|Akena Associates Ltd., Abuja, Nigeria|Makerere University School of Public Health, Kampala, Uganda",,https://ClinicalTrials.gov/show/NCT03568344,1,1
95,46,NCT01703884,ANC & Malaria Diagnostic in Pregnancy,AQUAMOD,Completed,No Results Available,Malaria,Drug: ASAQ,Placental malaria at delivery|The proportion of women with peripheral positive malaria infection at delivery,Centre Muraz|World Health Organization,Female,"16 Years to 50 Years   (Child, Adult)",Phase 4,5254.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,B00531,August 2012,July 2014,December 2014,"October 11, 2012",,"July 31, 2015","Dafra & Do districts, Bobo-Dioulasso, Hauts Bassins-houet, Burkina Faso",,https://ClinicalTrials.gov/show/NCT01703884,1,1
96,47,NCT01280162,Malaria Active Epidemiology and Treatment Study,,Completed,No Results Available,Malaria,Drug: Dihydroartemisinin piperaquine,Comparative efficacy.,"Armed Forces Research Institute of Medical Sciences, Thailand|United States Army Medical Materiel Development Activity",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,222.0,Other|U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WRAIR # 1737|HRPO Log Number A-16251,September 2010,February 2011,December 2012,"January 20, 2011",,"October 21, 2014","Oddar Meancheay, Oddar Meancheay, Cambodia",,https://ClinicalTrials.gov/show/NCT01280162,1,1
97,48,NCT02601716,PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults,,Completed,No Results Available,Malaria,Biological: PfSPZ Vaccine|Biological: CHMI (7G8)|Biological: CHMI (NF135.C10),Incidence and type of Adverse Events|Efficacy|Immunological response|Immunological outcomes,"Sanaria Inc.|Naval Medical Research Center|University of Maryland, College Park|Walter Reed Army Institute of Research (WRAIR)|Joint Warfighter Medical Research Program",All,18 Years to 50 Years   (Adult),Phase 2,92.0,Industry|U.S. Fed|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,NMRC.2015.0009|CVD Malaria 26000,January 2016,September 2017,November 2017,"November 10, 2015",,"October 16, 2018","University of Maryland-Baltimore, Center for Vaccine Development, Baltimore, Maryland, United States|Naval Medical Research Center, Silver Spring, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02601716,1,0
98,49,NCT01809873,Sustainable Financial Incentives To Improve Prescription Practices For Malaria,,Completed,No Results Available,Malaria,Behavioral: Performance based incentives,Proportion of children under 5 years of age who are treated with antimalarials following a negative malaria test,Duke University|Moi University,All,"Child, Adult, Older Adult",Not Applicable,14862.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research,Pro00035154,September 2012,November 2013,March 2014,"March 13, 2013",,"March 10, 2015","Moi University, Eldoret, Rift Valley Province, Kenya",,https://ClinicalTrials.gov/show/NCT01809873,1,1
99,50,NCT02389348,A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265,OZ/DSMCombo,Completed,No Results Available,Malaria,Drug: DSM265|Drug: OZ439,"PK/PD relationship on clearance of P falciparum parasites from the blood|Incidence, relation to study drug and severity of AE|Cmax, Tmax, AUC of DSM265 and OZ439",Medicines for Malaria Venture|Q-Pharm Pty Limited|QIMR Berghofer Medical Research Institute|Clinical Network Services (CNS) Pty Ltd,All,18 Years to 55 Years   (Adult),Phase 1|Phase 2,13.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QP14C12,February 2015,June 2015,June 2015,"March 17, 2015",,"October 7, 2015","Q-Pharm Clinics, Herston, Queensland, Australia",,https://ClinicalTrials.gov/show/NCT02389348,1,1
